Gain Therapeutics (GANX) Payables (2020 - 2025)
Historic Payables for Gain Therapeutics (GANX) over the last 6 years, with Q3 2025 value amounting to $1.6 million.
- Gain Therapeutics' Payables rose 4545.45% to $1.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $1.6 million, marking a year-over-year increase of 4545.45%. This contributed to the annual value of $946259.0 for FY2024, which is 2825.75% down from last year.
- As of Q3 2025, Gain Therapeutics' Payables stood at $1.6 million, which was up 4545.45% from $2.7 million recorded in Q2 2025.
- Gain Therapeutics' 5-year Payables high stood at $2.7 million for Q2 2025, and its period low was $560479.0 during Q4 2021.
- Moreover, its 5-year median value for Payables was $1.3 million (2023), whereas its average is $1.4 million.
- As far as peak fluctuations go, Gain Therapeutics' Payables tumbled by 4170.88% in 2021, and later skyrocketed by 19012.68% in 2022.
- Quarter analysis of 5 years shows Gain Therapeutics' Payables stood at $560479.0 in 2021, then soared by 190.13% to $1.6 million in 2022, then decreased by 18.89% to $1.3 million in 2023, then dropped by 28.26% to $946259.0 in 2024, then surged by 69.09% to $1.6 million in 2025.
- Its last three reported values are $1.6 million in Q3 2025, $2.7 million for Q2 2025, and $2.2 million during Q1 2025.